FDA Clears Ultragenyx UX016 for GNE Myopathy; Soligenix Advances HyBryte in CTCL
Ultragenyx received FDA clearance for UX016 in GNE myopathy, with a Phase 1/2 study planned for 2026. Soligenix's confirmatory HyBryte trial for CTCL has 66 of 80 patients enrolled, and an interim analysis is expected in early 2026.
Ultragenyx Pharmaceutical reported that the U.S. Food and Drug Administration cleared its Investigational New Drug application for UX016, a potential substrate replacement therapy for GNE myopathy, and a Phase 1/2 study is planned for 2026. In a separate rare disease program, Soligenix is nearing the conclusion of a confirmatory Phase 3 study for HyBryte, its lead candidate for cutaneous T-cell lymphoma (CTCL).
Despite the UX016 milestone, Ultragenyx's recent 30-day share price return declined 17.49%, its year-to-date share price return declined 18.22%, and its one-year total shareholder return declined 46.7%. The company holds a US$1.9 billion market cap and has ongoing losses against growing revenue.
Soligenix's lead candidate HyBryte is being developed for CTCL, a rare and chronic form of skin cancer. Unlike traditional DNA-damaging or chemotherapeutic agents, HyBryte is activated by visible fluorescent LED light rather than harmful UV rays. The drug is preferentially absorbed into malignant T-cells and, upon activation, generates high-energy singlet oxygen that shrinks lesions. Clinical data suggests responses can occur in as little as six weeks, while established treatments like Valchlor can take up to a year to show statistical significance. Soligenix is also exploring a home-use setting that would allow patients to treat themselves via telehealth.
After completing an initial Phase 3 study that hit all primary endpoints, health authorities requested a second, confirmatory study to provide a larger data set over a longer duration. As of February 2026, 66 of the required 80 patients are enrolled. An investigator-initiated study at the University of Pennsylvania showed a 75% response rate in patients after 18 weeks of treatment. An interim analysis is expected in early 2026, with top-line results following in the second half of the year.
Soligenix operates in the orphan disease space, defined as diseases affecting 200,000 people or less in the U.S., which offers tax credits, frequent FDA interaction, and priority review cycles that can cut approval times in half. The company has secured over $60 million in non-dilutive government funding to date. Beyond CTCL, Soligenix is exploring HyBryte for mild-to-moderate psoriasis and advancing Dusquetide (SGX945) for Behçet's Disease, a rare autoimmune condition characterized by painful ulcers.